ELDN

Eledon Pharmaceuticals, Inc.

Healthcare
Biotechnology
$215M market cap

Forecast run · Sep 14, 2026Upside rank 113 of 3,136

Model Signal

ForecastQ Daily Probabilities

72.3%

21.0%

37.6%

Analyst Consensus

Recommendation2.00/5 Buy

Last price$2.78

Price target$5.00

Implied move+79.9%

Analysts4

ForecastQ Portfolios

Healthcare Healthcare signal →

Company Profile

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.